Literature DB >> 19194875

Sporadic inclusion body myositis: pathogenic considerations.

George Karpati1, Erin K O'Ferrall.   

Abstract

Sporadic inclusion body myositis is the commonest acquired disease of skeletal muscles after 50 years of age, and as such it has commanded a great deal of attention of investigators over the past 25 years. As a result, a large amount of information has accumulated concerning its clinical profile, myopathology, and immunopathology. In the myopathology and immunopathology, there is general agreement that the characteristic features could be divided into a degenerative and an inflammatory group. However, there has been controversy about the possible role of these changes in the pathogenesis of muscle fiber damage. In particular, there is no agreement whether a cause-and-effect relationship exists between these two groups of changes, and if so, which is the primary one. In this brief overview, we examine the validity of the various controversial observations and critically review the justification for the two major hypotheses for the primary role of inflammation versus degeneration.

Entities:  

Mesh:

Year:  2009        PMID: 19194875     DOI: 10.1002/ana.21622

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

1.  Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Authors:  N A Goyal; T M Cash; U Alam; S Enam; P Tierney; N Araujo; F H Mozaffar; A Pestronk; T Mozaffar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-09       Impact factor: 10.154

Review 2.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

Review 3.  Novel therapeutic approaches for inclusion body myositis.

Authors:  Thomas E Lloyd
Journal:  Curr Opin Rheumatol       Date:  2010-11       Impact factor: 5.006

4.  Cytotoxic aggregation and amyloid formation by the myostatin precursor protein.

Authors:  Carlene S Starck; Andrew J Sutherland-Smith
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

5.  Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximab.

Authors:  Stefan Vordenbäumen; Eva Neuen-Jacob; Jutta Richter; Matthias Schneider
Journal:  Clin Rheumatol       Date:  2010-01-27       Impact factor: 2.980

6.  Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-γ signaling cascade in attacked versus nonattacked myofibers.

Authors:  Jana Ivanidze; Reinhard Hoffmann; Hanns Lochmüller; Andrew G Engel; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Am J Pathol       Date:  2011-09       Impact factor: 4.307

Review 7.  Theories of the pathogenesis of inclusion body myositis.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.686

8.  Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.

Authors:  Annie Hiniker; Brianne H Daniels; Han S Lee; Marta Margeta
Journal:  Acta Neuropathol Commun       Date:  2013-07-01       Impact factor: 7.801

Review 9.  Idiopathic Inflammatory Myopathies: Clinical Approach and Management.

Authors:  Asma Malik; Ghazala Hayat; Junaid S Kalia; Miguel A Guzman
Journal:  Front Neurol       Date:  2016-05-20       Impact factor: 4.003

Review 10.  Sporadic inclusion body myositis: the genetic contributions to the pathogenesis.

Authors:  Qiang Gang; Conceição Bettencourt; Pedro Machado; Michael G Hanna; Henry Houlden
Journal:  Orphanet J Rare Dis       Date:  2014-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.